Press Releases Latest Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment Press Releases Year None202420232022202120202019201820172016201520142013 May 04, 2023 Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison Apr 18, 2023 Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies Apr 12, 2023 Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023 Apr 03, 2023 Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model Mar 07, 2023 Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price Feb 28, 2023 Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022 Feb 28, 2023 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management Feb 22, 2023 Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV Feb 16, 2023 Theratechnologies Announces Path to Resume TH1902 Clinical Development First page « Previous page ‹ … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 … Next page › Last page » Displaying 71 - 80 of 379
Dec 18, 2024 Theratechnologies Announces Filing of FDA Prior Approval Supplement for EGRIFTA SV® Manufacturing Environment
May 04, 2023 Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Apr 18, 2023 Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Apr 03, 2023 Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
Mar 14, 2023 Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
Feb 28, 2023 Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
Feb 28, 2023 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
Feb 22, 2023 Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
